GLAXOSMITHKLINE PHARMA A/S: Financial statements 2024
CVR: 27394019
Source: annual report 2024, Danish Business Authority
01/01/2024 – 31/12/2024
GLAXOSMITHKLINE PHARMA A/S (CVR 27394019) has filed annual accounts for 2024. In 2024, the company reported revenue of DKK 548,470,000 and a net result of DKK 12,240,000 compared with DKK 12,003,000 the year before. That is an increase of 15.6% compared with the year before. The profit margin was 2.2%. Equity in the 2024 report amounted to DKK 38,129,000. The solvency ratio was 38.5%. The company had 73 employees in the financial year.
- Revenue
- DKK 548,470,000
- Gross Profit
- DKK 134,534,000
- Profit/Loss
- DKK 12,240,000
- Equity
- DKK 38,129,000
- Total Assets
- DKK 99,094,000
- Employees
- 73
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2024 | 548.5M | 134.5M | 12.2M | 38.1M | 73 |
| 2023 | 474.5M | 119.8M | 12M | 37.9M | 72 |
| 2022 | 440.3M | 126.2M | 11.1M | 36.9M | 68 |
| 2021 | 445.9M | 111.6M | 9M | 34.8M | 66 |
| 2020 | 441.7M | 120.3M | 12.3M | 37.8M | 62 |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2024
GLAXOSMITHKLINE PHARMA A/S has won the tender "Amgros 2025 1.474.a" issued by Amgros I/S worth 35,200,000 DKK.
GLAXOSMITHKLINE PHARMA A/S has won the tender "Amgros 2025 1.356.a" issued by Amgros I/S worth 4,530,400,000 DKK.
GLAXOSMITHKLINE PHARMA A/S has won the tender "Amgros 2025 1.1475.a" issued by Amgros I/S worth 23,300,000 DKK.
GLAXOSMITHKLINE PHARMA A/S has won the tender "Amgros 2025 1.1201.a" issued by Amgros I/S worth 45,354,771 DKK.
GLAXOSMITHKLINE PHARMA A/S has won the tender "Amgros 2025 1.701.a" issued by Amgros I/S worth 176,204,140 DKK.
GLAXOSMITHKLINE PHARMA A/S has published its annual report for 2023. Revenue came to DKK 474,477,000, and the net result was DKK 12,003,000.
GLAXOSMITHKLINE PHARMA A/S has won the tender "Amgros 2024 1.473.a" issued by Amgros I/S worth 5,780,000 DKK.
GLAXOSMITHKLINE PHARMA A/S has won the tender "Amgros 2024 1.472.a" issued by Amgros I/S worth 20,675,200,000 DKK.
About GLAXOSMITHKLINE PHARMA A/S
GLAXOSMITHKLINE PHARMA A/S is a Danish company of the type Aktieselskab based in Vallensbæk Strand, founded in 1968. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The company was previously named GLAXO DANMARK A/S and GLAXO WELLCOME A/S. The management consists of Diederik Maarten Eijsvogel. The board consists of Luciano Alves de Andrade (chair), Alastair William Jones, Diederik Maarten Eijsvogel and Helle Ann Hellberg. The company is owned by Setfirst Limited. The company has 83 employees (2026). In 2025, the company reported revenue of DKK 580,769,000 and a net result of DKK 13,123,000 compared with DKK 12,240,000 the year before. Equity in the 2025 report amounted to DKK 39,017,000.